PCSK9 and coronary artery disorder: As PCSK9 promotes LDLR degradation and prevents its recycling to the membrane, studies are now focusing on PCSK9 inhibitors as an emerging safe therapy for dyslipidemia supported by the fact that LOF mutations in PCSK9 are associated with reduced LDL-C levels and lower CHD risk (Cohen et al., 2006; Benn et al., 2010; Lambert et al., 2012).